What’s the current market cap for Tarsus Pharmaceuticals stock?

Tarsus Pharmaceuticals (TARS) has a market cap of $2.6bn as of June 06, 2026.

What is the P/E ratio for Tarsus Pharmaceuticals stock?

The price to earnings (P/E) ratio for Tarsus Pharmaceuticals (TARS) stock is 0 as of June 06, 2026.

Does Tarsus Pharmaceuticals stock pay dividends?

No, Tarsus Pharmaceuticals (TARS) stock does not pay dividends to its shareholders as of June 06, 2026.

When is the next Tarsus Pharmaceuticals dividend payment date?

Tarsus Pharmaceuticals (TARS) stock does not pay dividends to its shareholders.

What is the beta indicator for Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals (TARS) has a beta rating of 0.53. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Tarsus Pharmaceuticals stock | $TARS Share Price

13:30

15:10

16:45

18:25

20:00

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.

Ticker

$TARS

Sector

Health

Primary listing

NASDAQ

Employees

370

Headquarters

Irvine, United States

Website

tarsusrx.com

TARS Metrics

BasicAdvanced

$2.6bn

-$1.13

0.53

What the Analysts think about TARS

Analyst ratings (Buy, Hold, Sell) for Tarsus Pharmaceuticals stock.

Bulls say / Bears say

XDEMVY net product sales reached $145.4 million in Q1 2026, up more than 85 percent year-over-year and making up nearly 90 percent of total revenue of $162.1 million, signaling robust market adoption. (Tarsus 8-K Filing)

Tarsus reduced its net loss to $7.0 million in Q1 2026 from $25.1 million in the prior year while keeping gross margins near 94 percent, showing improved operating leverage as sales grow. (Tarsus 8-K Filing)

With $388.7 million in cash, cash equivalents, and marketable securities as of March 31, 2026 and a reaffirmed full-year XDEMVY sales outlook of $670–700 million, Tarsus is well funded to support ongoing commercialization and continue pipeline development. (Tarsus 8-K Filing)

Selling, general and administrative expenses increased to $136.4 million and research and development expenses to $22.4 million in Q1 2026, indicating high operating costs that continue to weigh on profitability. (Tarsus 8-K Filing)

In Q4 2025, XDEMVY net product sales were $451.4 million, delivering over 150 percent year-over-year sales growth and highlighting Tarsus’s current dependence on a single product for its entire revenue stream. (Tarsus press release)

Key pipeline drugs TP-04 (for ocular rosacea) and TP-05 (for Lyme disease prevention) are only in Phase 2 studies, with topline results not anticipated until the first half of 2027, extending diversification risk for at least another 18 months. (Tarsus press release)

Data summarised monthly by Lightyear AI. Last updated on 22 May 2026.

TARS Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

TARS Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $TARS

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

Data summarised monthly by Lightyear AI. Last updated on 22 May 2026.

About Tarsus Pharmaceuticals

Ticker

Employees

TARS Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about TARS

Analyst Ratings

Bulls say / Bears say

TARS Financial Performance

Income Statement

TARS Earnings Performance

Earnings per share (EPS)

Buy $TARS

Upcoming events

No upcoming events

Lightyear

Legal

Work with us

Bulls say / Bears say

Tarsus Pharmaceuticals/$TARS

About Tarsus Pharmaceuticals

Ticker

Employees

TARS Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about TARS

Analyst Ratings

Bulls say / Bears say

TARS Financial Performance

Income Statement

TARS Earnings Performance

Earnings per share (EPS)

Buy $TARS

Upcoming events

No upcoming events

What’s the current market cap for Tarsus Pharmaceuticals stock?

What is the P/E ratio for Tarsus Pharmaceuticals stock?

Does Tarsus Pharmaceuticals stock pay dividends?

When is the next Tarsus Pharmaceuticals dividend payment date?

What is the beta indicator for Tarsus Pharmaceuticals?

Bulls say / Bears say